Myo-Care: The Key To Better Vision
WAYS TO CONTROL MYOPIA
Myopia has seen a significant global rise in recent decades. It advances most
swiftly from ages 6 until early adulthood, underscoring the vital need for
early monitoring and intervention. Detecting and managing myopia early
gives the best results. Please see below, supported methods that effectively
manage and curb myopia progression.
AXIAL LENGTH MEASUREMENT
Once the eye has grown longer, there is no way we can shrink the eye again. Our treatment for myopia aims to reduce the rate of eye growth and keep eye growth within normal limits. The only true way of checking the effectiveness of treatment is by measuring the axial length of your child’s
eyes.
IOL MASTER BIOMETRY ASSESSMENT
Axial length biometry and the charting Axial Length over time is the gold standard of care. It is the only true way to monitor the effectiveness of the your child’s myopia control treatment.
Our Optometrist can chart your child’s eye growth
Central optical zone surrounded by defocus area
NEW SPECTACLE LENSES TO TREAT MYOPIA
There are three new spectacle lenses that show great promise in effectively slowing myopia. They are Essilor Stellest, Zeiss Myocare and Hoya Mi Yosmart lenses.
These special lenses can slow myopia progression by an average of 60-67%. These lenses use a technology that has a clear central optical zone surrounded by many ‘defocus segments’. It is these “defocus segments” that help to control myopia progression.
ORTHOKERATOLOGY “SLEEP LENSES” FOR MYOPIA CONTROL
Children wear ortho-k lenses while asleep and enjoy clarity of vision in the morning and throughout the day! This surgery-free correction to myopia, gently reshapes their corneas while they sleep and is recommended for children who need myopia control therapy but want to be free of wearing spectacles and contact
lenses during day. Ortho-K lenses provide clear central vision while creating a zone of peripheral defocus which retards and slows down eye growth.
In recent decades, Orthokeratology has gained popularity, driven by accumulating evidence showing its effectiveness in not only providing short-term myopia correction but also in slowing down myopia progression over the long term.
SOFT MULTIFOCAL CONTACT LENSES FOR MYOPIA CONTROL
Multifocal 1 Day contact lenses are now used as an effective option to
reduce the progression of myopia. Like orthokeratology, these lenses blur the
image that falls on the peripheral retina. This does nothing to compromise central vision and is not usually noticeable to the wearer. This peripheral defocus is the key to slowing down the progression of myopia.
ATROPINE EYE DROPS
Recent studies such as the Atropine in the Treatment of Myopia (ATOM) project provide strong evidence to support the use of low concentration atropine eyedrops to retard the progression of myopia. Atropine is a prescription-only medication, Atropine acts to relax the eye’s focusing system and may slightly enlarge the pupil. Atropine drops can have some mild side-effects.
REPEATED LOW-LEVEL RED-LIGHT MYOPIA THERAPY AT HOME
SAVING SIGHT SOONER MAKES BRIGHTER FUTURES
Repeated Low-Level Red-Light Myopia therapy at home has been shown to slow down the progression of myopia. It does this by improving the metabolic rate and circulation of the eye. Repeated Low-Level Red-Light (RLRL) therapy, is a highly effective and child-friendly way to slow the progression of myopia.
Designed to be easy and convenient to use at home, the therapy involves looking into the device for 3 minutes of treatment, 2 times per day, 5 days per week, with a minimum of 4 hours between sessions. The device is controlled with a simple touchscreen and tracks each child’s use. It can also be monitored by your optometrist and programmed to send SMS reminders to patient’s guardian.
Is this device safe?
It is free of any known significant side effects; and is suitable for use by children as young as 3 and up to 16. International approvals & regulatory status. The Eyerising Myopia Management Device meets the quality, safety, and efficacy standards required by medical regulators in over 30 countries across Europe and Australasia.*
HOW EFFECTIVE RLRL?
Clinically tested for trusted results The Eyerising Myopia Management Device has been proven in published clinical trials to be effective in the treatment of myopia, slowing its progression by up to 87.7%.1 RLRL therapy’s efficacy and safety has been validated through a comprehensive ongoing clinical trial program. The results, published in leading peer-reviewed scientific publications show that with >75% compliance, exposure to RLRL therapy can control the progression of myopia.
MYO-CONTROL PLAN is included FREE with our RLRL Program for the first year of treatment!
*Eyerising Myopia Device has been cleared as a medical device by the following regulators: CE (EU), TGA (AU), Medsafe (NZ), and MHRA (UK), with other regulatory clearances expected imminently. Eyerising International is ISO 13485:2016 certified by notified body BSI.
